Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML
- 21 February 2024
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 99 (5) , 862-870
Abstract
Multiparameter flow cytometry (MFC) measurable residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) independently predicts poor outcomes in acute myeloid leukemia (AML). Conversely, its prognostic value in the newly defined disease entity, myelodysplastic neoplasm (MDS)/AML is unknown. To assess the relationship between disease type, pre‐HCT MRD, and post‐HCT outcomes, we retrospectively analyzed 1265 adults with MDS/AML (n = 151) or AML (n = 1114) who received a first allograft in first or second morphologic remission at a single institution between April 2006 and March 2023. At 3 years, relapse rates (29% for MDS/AML vs. 29% for AML, p = .98), relapse‐free survival (RFS; 50% vs. 55%, p = .22), overall survival (OS; 52% vs. 60%, p = .073), and non‐relapse mortality (22% vs. 16%, p = .14) were not statistically significantly different. However, a significant interaction was found between pre‐HCT MFC MRD and disease type (MDS/AML vs. AML) for relapse (p = .009), RFS (p = .011), and OS (p = .039). The interaction models indicated that the hazard ratios (HRs) for the association between pre‐HCT MRD and post‐HCT outcomes were lower in patients with MDS/AML (for relapse: HR = 1.75 [0.97–3.15] in MDS/AML vs. 4.13 [3.31–5.16] in AML; for RFS: HR = 1.58 [1.02–2.45] vs. 2.98 [2.48–3.58]; for OS: HR = 1.50 [0.96–2.35] vs. 2.52 [2.09–3.06]). On the other hand, residual cytogenetic abnormalities at the time of HCT were equally informative in MDS/AML as in AML patients. Our data indicate that MFC‐based pre‐HCT MRD testing, but not testing for residual cytogenetic abnormalities, is less informative for MDS/AML than AML patients when used for prognostication of post‐HCT outcomes.Keywords
Funding Information
- National Institutes of Health (P01‐CA078902, P01‐CA018029, P30‐CA015704)
This publication has 34 references indexed in Scilit:
- Poor pretransplantation minimal residual disease clearance as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess blasts: A multicenter, retrospective cohort studyCancer, 2023
- Relationship Between Pretransplantation Nutritional Status and Outcome in Adults with Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2022
- Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal ApproachCurrent Protocols in Cytometry, 2020
- Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual diseaseLeukemia, 2019
- Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic TransplantationTransplantation and Cellular Therapy, 2017
- Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic SyndromeTransplantation and Cellular Therapy, 2016
- Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemiaLeukemia, 2016
- Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantationLeukemia, 2014
- Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete RemissionTransplantation and Cellular Therapy, 2013
- Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantationCancer, 2011